Tetrahydroxycurcumin has been demonstrated to dose‐ and time‐dependently reduce the amount of KLF5 protein in 5637 and WH cells of bladder cancer, indicating a post‐transcriptional regulation mechanism without altering mRNA expression (Cecil et al. 2022). Here, KLF5 is linked to urinary bladder carcinoma.